Determination of ropinirole in human plasma by ultra performance liquid chromatography-tandem mass spectrometry

被引：0
|
作者：
Wang, Hong-Yun [1 ]
Liu, Ming [1 ]
Hu, Pei [1 ]
Jiang, Ji [1 ]
机构：
[1] Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing
来源：
Journal of Chinese Mass Spectrometry Society | 2015年 / 36卷 / 04期
关键词：
Pharmacokinetics; Plasma concentration; Ropinirole; Ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS);
D O I：
10.7538/zpxb.youxian.2015.0014
中图分类号：
学科分类号：
摘要：
A method of ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the determination of ropinirole in human plasma. The plasma samples were extracted with methyl tert-butyl ether after the addition of deuterated internal standard. The analytical column was Acuity UPLC BEH C18 column (2.1 mm×50 mm×1.7 μm), and the mobile phase was composed of methanol-10 mmol/L ammonium formate in 0.2% ammonium solution (80:20, V/V). The flow rate was 0.4 mL/min. Detection was performed with multiple reactions monitoring (MRM) using positive electrospray ionization(ESI). The results show that the calibration curve is linear over the concentration range of 0.02-5 μg/L. The lower limit of quantification is 0.02 μg/L. Inter-day and intra-day precision are less than 15%, and the accuracy is within 85%-115%. Extraction recoveries are around 85% and the determination is independent of plasma matrix. In addition, the analyte is proved to be stable under various storage and processing conditions. Therefore, this method proves to be rapid, sensitive and specific, and suitable for the pharmacokinetic study of ropinirole in humans. ©, 2015, Chinese Society for Mass Spectrometry. All right reserved.
引用
收藏
页码：296 / 301
页数：5
相关论文
共 11 条
  • [1] Nashatizadeh M.M., Lyons K.E., Pahwa R., A review of ropinirole prolonged release in Parkinson's disease, Clinical Interventions in Aging, 4, pp. 179-186, (2009)
  • [2] Shill H.A., Stacy M., Update on ropinirole in the treatment of Parkinson's disease, Neuropsychiatric Disease and Treatment, 5, pp. 33-36, (2009)
  • [3] Kulisevsky J., Pagonabarraga J., Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: Meta-analysis of randomized controlled trials, Drug Safety, 33, 2, pp. 147-161, (2010)
  • [4] Lieberman A., Olanow C.W., Sethi K., Et al., A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease, Neurology, 51, 4, pp. 1057-1062, (1998)
  • [5] Pahwa R., Stacy M.A., Factor S.A., Et al., Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease, Neurology, 68, 14, pp. 1108-1115, (2007)
  • [6] Wen A., Chen S., Yang Z., Et al., Study on pharmacokinetics of ropinirole tablets in healthy volunteers, Chinese Journal of Hospital Pharmacy, 27, 6, pp. 729-731, (2007)
  • [7] Ding L., Yang L., Wang M., Et al., A LC-MS/MS method for determination of ropinirole in healthy volunteers and application to pharmacokinetics study of ropinirole and it combined with levodopa and benserazide tablets, Chinese Journal of New Drugs and Clinical Remedies, 32, 3, pp. 240-244, (2013)
  • [8] Wen H., Zhong X., Yi Z., Et al., Determination of ropinirole in animal plasma, Chinese Journal of Spectroscopy Laboratory, 27, 6, pp. 2139-2145, (2010)
  • [9] Bharathi D.V., Jagadeesh B., Kumar S.S., Et al., Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: Application to a clinical pharmacokinetic study, Biomedical Chromatography, 23, 5, pp. 557-562, (2009)
  • [10] Bhatt J., Jangid A., Shetty R., Et al., Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma, Journal of Pharmaceutical and Biomedical Analysis, 40, 5, pp. 1202-1208, (2006)
12